Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2025-26/065 dated 4th February, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e.10th February, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2025.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt reported strong Q3 FY26 results, with standalone revenue rising about 32% year-on-year to Rs 430 crore and a net profit of Rs 28 crore versus a loss of Rs 22 crore in the same quarter last year. Consolidated Q3 revenue grew around 23% YoY to Rs 888 crore, with profit after tax at Rs 61 crore against Rs 20 crore a year ago. For the nine-month period, standalone profit turned around sharply to Rs 150 crore from a loss of Rs 52 crore in the prior year, reflecting both revenue growth and improved margins. The nine-month consolidated numbers, however, include a one-time exceptional charge of Rs 107 crore — mainly Rs 97 crore from deconsolidating two US subsidiaries (Morton Grove Pharmaceuticals and Wockhardt USA LLC) after the company filed for Chapter 7 bankruptcy to exit the loss-making US generic pharma business — plus Rs 10 crore for the new Labour Codes. The auditor's limited review report was clean with no qualifications.
Strong YoY revenue growth and a clear return to profitability are positive for shareholders, suggesting improved core operations. The one-time US exit charge is a strategic reset that should clean up the portfolio and support better future margins, though the stock may react to the headline Rs 107 crore exceptional drag in the nine-month numbers.